RxDoctor Payments Data

Michael Lansing

Pulmonary Disease · Pikesville, MDNPI 1962483230

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $77,150 of the $84,694 with a category attached, or 91.1%. GSK accounts for 97.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $61,945 and has fallen 95.7% since, to $2,638 in 2021. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,694in general payments, 2019–2025

Across 201 payments — averaging $421.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$83K
  • Boehringer Ingelheim$426
  • Insmed, Inc.$270
  • Grifols USA, LLC$257
  • Mylan Specialty L.p.$239
  • AstraZeneca$177
  • plus $387 from 13 others

What the payments were for

  • Speaking & faculty fees$77,15091%
  • Travel & lodging$3,0374%
  • Food & beverage$4,5075%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,694 in reported general payments places this provider in the 90th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Other pulmonary disease in Pikesville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →